AUTHORS
Karan L. Chohan, MD, Fuliang Chu, PhD2, Paolo Strati, MD3, Jason Westin, MD, MS, FACP, FASCO4, Luis E. Fayad, MD5, Sairah Ahmed, MD6, Ayushi Chauhan, MD7, Dai Chihara, MD, PhD8, Anath Christopher Lionel, MD, PhD9, Frederick B. Hagemeister, MD10, Swaminathan P. Iyer, MD11, Ranjit Nair, MD12, Luis Malpica, MD13, Chijioke C Nze, MD, MPH14, Fateeha Furqan, MBBS15, Mark Hamilton, MD, PhD16, Neha Akkad, MD17, Robert Harkins, MD, MS18, Faezeh Darbaniyan, PhD19, Jingjing Cao, BSc20, Cara Haymaker21, Seoung Ae Lee22, Swapna Binoy23, Hanh Chu24, Jiayan Li25, Prashant S Menon26, Navin Varadarajan, PhD27, Jon Pileggi28, Katrina Adlerz29, Fengguang Guo30, Claudia Kettlun, PhD31, Khushi Patel32, Ahmed G. Elsaeed33, Tania Patricia Sainz, BS34, Francisco Vega Sr, MD PHD35, Lei Feng, MS36, Ryan Sun37, Christopher R. Flowers Jr, MD, MS38, Sattva S Neelapu Sr, MD39
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, United States
2 The University of Texas MD Anderson Cancer Center, Houston, United States
3 The University of Texas MD Anderson Cancer Center, Houston, United States
4 The University of Texas MD Anderson Cancer Center, Houston, United States
5 The University of Texas MD Anderson Cancer Center, Houston, United States
6 The University of Texas MD Anderson Cancer Center, Houston, United States
7 The University of Texas MD Anderson Cancer Center, Houston, United States
8 The University of Texas MD Anderson Cancer Center, Houston, United States
9 The University of Texas MD Anderson Cancer Center, Houston, United States
10 The University of Texas MD Anderson Cancer Center, Houston, United States
11 The University of Texas MD Anderson Cancer Center, Houston, United States
12 The University of Texas MD Anderson Cancer Center, Houston, United States
13 The University of Texas MD Anderson Cancer Center, Houston, United States
14 The University of Texas MD Anderson Cancer Center, Houston, United States
15 The University of Texas MD Anderson Cancer Center, Houston, United States
16 The University of Texas MD Anderson Cancer Center, Houston, United States
17 The University of Texas MD Anderson Cancer Center, Houston, United States
18 The University of Texas MD Anderson Cancer Center, Houston, United States
19 The University of Texas MD Anderson Cancer Center, Houston, United States
20 The University of Texas MD Anderson Cancer Center, Houston, United States
21 The University of Texas MD Anderson Cancer Center, Houston, United States
22 The University of Texas MD Anderson Cancer Center, Houston, United States
23 The University of Texas MD Anderson Cancer Center, Houston, United States
24 The University of Texas MD Anderson Cancer Center, Houston, United States
25 University of Houston, Houston, United States
26 University of Houston, Houston, United States
27 University of Houston, Houston, United States
28 Cell Therapy Manufacturing Center (CTMC), Houston, United States
29 Cell Therapy Manufacturing Center (CTMC), Houston, United States
30 Cell Therapy Manufacturing Center (CTMC), Houston, United States
31 The University of Texas MD Anderson Cancer Center, Houston, United States
32 The University of Texas MD Anderson Cancer Center, Houston, United States
33 The University of Texas MD Anderson Cancer Center, Houston, United States
34 The University of Texas MD Anderson Cancer Center, Houston, United States
35 The University of Texas MD Anderson Cancer Center, Houston, United States
36 The University of Texas MD Anderson Cancer Center, Houston, United States
37 The University of Texas MD Anderson Cancer Center, Houston, United States
38 The University of Texas MD Anderson Cancer Center, Houston, United States
39 The University of Texas MD Anderson Cancer Center, Houston, United States
ABSTRACT
Introduction: CD19-directed CAR T-cell therapy has improved outcomes in large B-cell lymphoma (LBCL), but CD19 loss or downregulation is a frequent cause of relapse. CD79b, a B-cell receptor component retained across B-cell lymphomas, including CD19-negative relapses, offers a rational alternative target. JV-213 is an autologous CD79b-directed CAR T-cell product incorporating OX40 costimulation, binding an epitope distinct from polatuzumab vedotin, that showed potent preclinical activity (Chu et al., 2023). We report preliminary safety and efficacy from dose escalation of the first-in-human study of JV-213.
Methods: This phase 1, single-center, open-label study (NCT05773040) evaluates JV-213 in adults with relapsed/refractory (R/R) B-cell lymphoma using a 3+3 dose-escalation design (4 dose levels [DL], 50/100/200/500 ×106 CAR+ T cells), followed by expansion at the MTD/RP2D. Eligible patients (pts) had R/R B-cell lymphoma after ≥2 prior lines, ECOG 0-1, and adequate organ function; prior CD19 CAR T allowed. Primary endpoints were safety and determination of the MTD/RP2D. Secondary endpoints included ORR, CR rate, DOR, PFS, and OS. Assessments of CAR T kinetics/pharmacodynamics and biomarkers of response, resistance, and toxicity were exploratory endpoints.
Results: Of 20 pts enrolled, 18 underwent apheresis (2 screen failures), and 14 products were successfully manufactured (4 manufacturing failures). A manufacturing update from Process 1.0/1.1 to 1.2 reduced failure rates from 44% (4/9 pts) to 0% (0/9). At data cutoff, 12 pts had been infused (8 with Process 1.2), 3 at each of the 4 DLs; of the remaining 2 products, 1 pt was not infused due to an AE prior to lymphodepletion, and 1 was awaiting infusion. Twelve pts were safety evaluable and 11 efficacy evaluable. Pts had a median age of 61 years (range 33-84) and a median of 4 prior lines of therapy (range 2-6); 75% (9/12) had prior CD19-directed CAR T-cell therapy and 33% prior polatuzumab. Diagnoses were LBCL (75%), FL (17%), and Burkitt lymphoma (8%); 67% had stage III-IV disease, and 50% had elevated LDH. Cell of origin was GCB in 63% (5/8) of evaluable LBCL pts.
CAR T-cell-specific toxicities were infrequent and predominantly low-grade: CRS in 3 pts (25%, all grade 1-2), ICANS in 1 (8%, grade 1), and IEC-HS in 1 (8%, grade 3), with no grade ≥3 CRS or ICANS. No dose-limiting toxicities (DLTs) have been observed across all 4 DLs. Tocilizumab, steroids, and anakinra were used in 17%, 17%, and 8% of pts, respectively. Common AEs were fatigue and thrombocytopenia (83% each), and neutropenia and anemia (75% each). Grade ≥3 cytopenias were common (neutropenia 67%, thrombocytopenia 50%, anemia 42%), with prolonged cytopenias and IVIG use noted in 25% each. One grade 3 infection occurred; no MDS was observed.
Across all DLs, ORR was 36% (4/11) with CR in 27% (3/11). Process 1.2 (n=8; 7 efficacy evaluable) was associated with improved efficacy vs Process 1.0/1.1 (n=4) (ORR/CR 43%/43% vs 25%/0%), without increased toxicity. Three of 4 responses occurred after prior CD19 CAR T (2 CR in LBCL, 1 PR). The longest response is ongoing at 12 months.
Peak CAR T expansion was dose-dependent, with highest levels observed at DLs 3-4, occurring 1-2 weeks post-infusion. Peak granzyme A/B levels in plasma also increased with dose, supporting enhanced effector function at higher doses. CD79b was positive by IHC in all 7 baseline tumor samples assessed (6 strong, 1 weak). Among 5 paired baseline and progression samples, CD79b was retained at progression in 3/5 and weak/negative in 2/5, suggesting antigen escape as a possible resistance mechanism. With Process 1.2, transduction efficiency more than tripled (73.5% vs 22.0% CAR+ T cells, p=0.0002), vector copy number per transduced cell increased (3.8 vs 2.5, p=0.002), and CAR+ T-cell yield increased ~8-fold (1120M vs 133M, p=0.002).
Conclusion: JV-213, a novel CD79b-directed CAR T-cell therapy, was well tolerated in a heavily pretreated, largely CD19-CAR-relapsed population, with no grade ≥3 CRS or ICANS and no DLTs across all 4 DLs. Optimized manufacturing (Process 1.2) improved transduction efficiency and yield, eliminated failures, and was associated with higher efficacy (ORR 43%, CR 43%), including LBCL pts with prior CD19 CAR T. CAR T expansion and plasma granzyme A/B levels increased with dose. Single-cell functional and transcriptional profiling of CAR T products, with correlation to response, will be presented. Dose expansion is ongoing.
DISCLOSURES
Karan L. Chohan, MD: No relevant conflicts of interest to declare.